ライフサイエンスコーパス: bronchiectasis

1 curred later, and lung disease was moderate (bronchiectasis).

2 rkers of disease severity and progression in bronchiectasis.

3 the independent adjusted prognostic value of bronchiectasis.

4 rtant modifier of disease severity in non-CF bronchiectasis.

5 cystic fibrosis, and age-dependent onset of bronchiectasis.

6 y on disease severity in non-cystic fibrosis bronchiectasis.

7 h exacerbations and lung function decline in bronchiectasis.

8 ession, predicting lung function decline and bronchiectasis.

9 c role for S. mucilaginosus in patients with bronchiectasis.

10 is in patients with non-cystic fibrosis (CF) bronchiectasis.

11 ung infection, particularly in patients with bronchiectasis.

12 , chronic obstructive pulmonary disease, and bronchiectasis.

13 e pulmonary disease, pulmonary fibrosis, and bronchiectasis.

14 atients with cystic fibrosis (CF) and non-CF bronchiectasis.

15 zygosity are associated with the presence of bronchiectasis.

16 tions by genotyping patients with idiopathic bronchiectasis.

17 tion of genetic susceptibility in idiopathic bronchiectasis.

18 nd/or reticular pattern, often with traction bronchiectasis.

19 cular pattern with honeycombing and traction bronchiectasis.

20 utum of a poodle-owning patient with chronic bronchiectasis.

21 that leads to chronic airway obstruction and bronchiectasis.

22 ), and 87% occurred in patients with nodular bronchiectasis.

23 ed from new strains in patients with nodular bronchiectasis.

24 ases also occur in severe COPD as they do in bronchiectasis.

25 inusitis, laryngitis, asthma, pneumonia, and bronchiectasis.

26 onchiectasis, ANCA-associated vasculitis and bronchiectasis.

27 ean of only 5 pack-years, and had multifocal bronchiectasis.

28 tality and disease outcomes in patients with bronchiectasis.

29 aride plays an important part, one developed bronchiectasis.

30 er-lobe cavitary disease and 50% had nodular bronchiectasis.

31 nt available for health status assessment in bronchiectasis.

32 itions that may predispose to development of bronchiectasis.

33 n patients with emphysema and diffuse cystic bronchiectasis.

34 Six (43%) of 14 patients had CT evidence of bronchiectasis.

35 ive value (50-55%) to detect the presence of bronchiectasis.

36 ease severity and future risk in adults with bronchiectasis.

37 alities, pulmonary arterial enlargement, and bronchiectasis.

38 the brother was fairly asymptomatic but had bronchiectasis.

39 clinical and research tool in patients with bronchiectasis.

40 ss syndrome, pneumonia, cystic fibrosis, and bronchiectasis.

41 on, and increased mortality in patients with bronchiectasis.

42 nti-inflammatory treatment for patients with bronchiectasis.

43 icrobiota in people with non-cystic fibrosis bronchiectasis.

44 om 53 of 842 (6.3%) to 53 of 1465 (3.6%) for bronchiectasis.

45 ronic respiratory infections associated with bronchiectasis.

46 vastatin could reduce cough in patients with bronchiectasis.

47 n of respiratory microbiota in patients with bronchiectasis.

48 bronchial thickening, pleural thickening and bronchiectasis.

49 on a quality-of-life scale in patients with bronchiectasis.

50 ication tools for morbidity and mortality in bronchiectasis.

51 er findings also suggest a benefit in non-CF bronchiectasis.

52 t of patients with adult non-cystic fibrosis bronchiectasis.

53 , pneumonia (6.3% vs. 2.3%, P < 0.0001), and bronchiectasis (1.0% vs. 0.1%, P < 0.0001).

54 1.27), pulmonary fibrosis (1.36; 1.25-1.48), bronchiectasis (1.26; 1.09-1.47), pulmonary collapse (1.

55 mmunity, 28.6%; chronic lung disease, 28.5%; bronchiectasis, 11.2%; gastrointestinal inflammatory dis

56 ure (4; 14%), limb lymphoedema (3; 10%), and bronchiectasis (2; 7%).

57 Other findings included bronchiectasis (48%), pleural thickening (40%), ground g

58 (P = 0.005)), and an increased frequency of bronchiectasis (54.5%, P < 0.001), tree-in-bud (18.7%, P

59 termine causative factors in 150 adults with bronchiectasis (56 male, 94 female) identified using hig

60 f the 5 year mortality rate to construct the Bronchiectasis Aetiology Comorbidity Index (BACI).

61 In vitro, cystic fibrosis and bronchiectasis airway fluid directly inhibited apoptotic

62 x-point scale) of emphysema, the presence of bronchiectasis, airway wall thickening, and tracheal abn

63 linical outcomes in non-cystic fibrosis (CF) bronchiectasis, although associated risks of macrolide r

64 ic virus 1 (HTLV-1) might be associated with bronchiectasis among Indigenous Australians.

65 tment of cystic fibrosis, noncystic fibrosis bronchiectasis, ANCA-associated vasculitis and bronchiec

66 omic DNA from 96 individuals with idiopathic bronchiectasis and 101 control subjects was analyzed by

67 four (47%) patients had nodular disease with bronchiectasis and 27 (53%) had upper lobe cavitary dise

68 Netherlands among 83 outpatients with non-CF bronchiectasis and 3 or more lower respiratory tract inf

69 We included 470 patients with bronchiectasis and 414 controls.

70 recruited patients with non-cystic fibrosis bronchiectasis and age-matched and sex-matched controls

71 ) in adult patients with non-cystic fibrosis bronchiectasis and at least two infective exacerbations

72 Multimorbidity is frequent in bronchiectasis and can negatively affect survival.

73 tem spleen sample of a woman presenting with bronchiectasis and cavitary lung disease associated with

74 fibrosis (CF) lung disease as well as non-CF bronchiectasis and chronic obstructive airways disease.

75 Patients with bronchiectasis and chronic P. aeruginosa infection were

76 ffective treatment in adherent patients with bronchiectasis and chronic P. aeruginosa infection.

77 hickening, airway smooth muscle hypertrophy, bronchiectasis and emphysema.

78 radiologists for the presence and extent of bronchiectasis and emphysema.

79 o investigate comorbidities in patients with bronchiectasis and establish their prognostic value on d

80 (AZLI) in patients with non-cystic fibrosis bronchiectasis and Gram-negative bacterial colonisation.

81 Such infections are associated with bronchiectasis and high mortality rates, making them a s

82 uded patients aged 18 years or older who had bronchiectasis and history of positive sputum or broncho

83 ctive cohort study of Indigenous adults with bronchiectasis and known HTLV-1 serologic status admitte

84 DESIGN, SETTING, AND PARTICIPANTS: The BAT (Bronchiectasis and Long-term Azithromycin Treatment) stu

85 o information about the relationship between bronchiectasis and mortality in patients with COPD is cu

86 at in a significant portion of patients with bronchiectasis and Pseudomonas aeruginosa lung infection

87 ed tobramycin for treatment of patients with bronchiectasis and Pseudomonas aeruginosa.

88 and early-onset pulmonary disease including bronchiectasis and pulmonary emphysema.

89 ota is present in the lungs of patients with bronchiectasis and remains stable through treatment of e

90 tion and inflammation leading to progressive bronchiectasis and respiratory failure.

91 and personalized microbiome in patients with bronchiectasis and suggest a pathogenic role for S. muci

92 s structural pulmonary abnormalities such as bronchiectasis and trapped air, at an early stage, befor

93 ection contributes to the risk of developing bronchiectasis and worsens outcomes among Indigenous Aus

94 for ground-glass opacity, reticulation, and bronchiectasis and/or bronchiolectasis and (b) identical

95 Many patients develop central bronchiectasis, and a subset will go on to endstage fibr

96 (GGO), reticulation, honeycombing, nodules, bronchiectasis, and air trapping were assessed retrospec

97 dex correlates with extent of total disease, bronchiectasis, and air trapping.

98 ngs of extensive reticular pattern, traction bronchiectasis, and honeycombing are closely related to

99 increased total IgE and specific IgE levels, bronchiectasis, and mold colonization of the airways.

100 Two patients had diffuse cystic bronchiectasis, and neither reported a history of illnes

101 rom several cancers, ischemic heart disease, bronchiectasis, and other diseases.

102 G anti-Af antibodies, pulmonary infiltrates, bronchiectasis, and pulmonary fibrosis.

103 the disease outcomes, such as development of bronchiectasis, anogenital dysplasia, or invasive cancer

104 ed odds ratio [aOR] 5.65, 95% CI 5.52-5.79), bronchiectasis (aOR 4.65, 95% CI 4.26-5.08), eczema/psor

105 In one of the girls, bronchiectasis appeared at follow-up.

106 High airway bacterial loads in non-CF bronchiectasis are associated with airway and systemic i

107 number of therapies for non-cystic fibrosis bronchiectasis are undergoing testing in clinical resear

108 cant clinical benefit in non-cystic fibrosis bronchiectasis, as measured by QOL-B-RSS, suggesting a c

109 screened in familial pulmonary diseases with bronchiectasis, associated with a medical history of vis

110 es that commonly involve bronchioles include bronchiectasis, asthma, and chronic obstructive pulmonar

111 hronic obstructive pulmonary disease (COPD), bronchiectasis, asthma, and lung cancer.

112 The point prevalence of bronchiectasis at each visit increased from 29.3% at 3 m

113 with or without malabsorption, but not with bronchiectasis, autoimmunity, other cancers, granulomato

114 otracted bacterial bronchitis (PBB) and mild bronchiectasis (BE).

115 tibiotic therapy can be initiated to prevent bronchiectasis, but also to avoid inappropriate immunosu

116 eparate proportions of total disease (%Dis), bronchiectasis (%Bx), and trapped air (%TA) were determi

117 alities including bronchial wall thickening, bronchiectasis, centrilobular opacities, and air trappin

118 establish chronic respiratory infections in bronchiectasis, chronic obstructive pulmonary disease, a

119 ts with cystic fibrosis, non-cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease, a

120 hed and sex-matched controls at a specialist bronchiectasis clinic in Edinburgh, UK.

121 rapy may suffice in certain conditions, like bronchiectasis, coagulopathies, Goodpasture's syndrome,

122 Eligible patients were those with bronchiectasis confirmed by high-resolution CT and a com

123 Bronchiectasis develops early in the course of cystic fi

124 rial infections of the respiratory tract and bronchiectasis, even with adequate immunoglobulin replac

125 patient with a history of asthma and chronic bronchiectasis experiencing right-middle-lobe syndrome g

126 isk factors associated with the detection of bronchiectasis from 3 months to 3 years of age.

127 ticentre cohort analysis of outpatients with bronchiectasis from four European centres followed up fo

128 airways of patients with cystic fibrosis or bronchiectasis from other causes and appears to have evo

129 ange, 1 to 9) were identified in the nodular bronchiectasis group, with 15 of 17 patients (88%) havin

130 rrent bacterial and candidal infections with bronchiectasis, growth delay, and early death.

131 Patients with bronchiectasis had higher levels of airway inflammatory

132 55 (12%) patients with bronchiectasis had low-expressing genotypes.

133 Patients with bronchiectasis had significantly higher infection scores

134 f inhaled antibiotics in non-cystic fibrosis bronchiectasis has not been established in randomised co

135 data demonstrate that patients with nodular bronchiectasis have multiple and/or repeated infections

136 presented with recurrent infections, eczema, bronchiectasis, high IgE, eosinophilia, defective B cell

137 attern and were more likely to have traction bronchiectasis, honeycombing, and a UIP pattern than tho

138 ), chronic obstructive pulmonary disease and bronchiectasis (HR 1.55, 95 % CI: 1.17-2.04), malnutriti

139 cient , 0.96) with regard to the severity of bronchiectasis ( ICC intraclass correlation coefficient

140 Participants had clinically significant bronchiectasis (ie, cough and sputum production when cli

141 culation, tiny nodules, altered attenuation, bronchiectasis), image quality (graded by using a six-po

142 viduals with cystic fibrosis (CF) and non-CF bronchiectasis, impacting morbidity and mortality.

143 The severity of bronchiectasis in children with cystic fibrosis is signi

144 luid in early life was associated with early bronchiectasis in children with cystic fibrosis.

145 the clinical characteristics and outcomes of bronchiectasis in this population, according to HTLV-1 s

146 lace chest computed tomography to screen for bronchiectasis in this population.

147 ng chronic obstructive pulmonary disease and bronchiectasis in women, are associated with solid fuel

148 Bronchiectasis is a disorder of persistent lung inflamma

149 Bronchiectasis is a pathologic description of lung damag

150 Bronchiectasis is characterised by chronic cough, sputum

151 The prevalence of bronchiectasis is high in patients with moderate-to-seve

152 he long-term treatment of chronic asthma and bronchiectasis is less well established.

153 remodeling (healed cavitation, fibrosis, and bronchiectasis) is a major cause of lung disability, sur

154 tigation of this population of patients with bronchiectasis led to identification of one or more caus

155 istent with changes observed in CF and other bronchiectasis lungs.

156 ce of apoptotic cells in cystic fibrosis and bronchiectasis may be due to elastase-mediated cleavage

157 Bronchiectasis may be more common in patients with alpha

158 Bronchiectasis may present in autoimmune disease, as wel

159 -year-old IDA/CA/MTD group had more lobes of bronchiectasis (median, 5; P = 0.0008) and consolidation

160 coidosis, such as pulmonary hypertension and bronchiectasis, might also contribute to an increase in

161 rlaid on 10 axial slices for the presence of bronchiectasis, mucous plugging, or other airway abnorma

162 MRI demonstrated bronchial wall thickening/bronchiectasis, mucus plugging, and perfusion deficits f

163 nce of increased mortality from lung cancer, bronchiectasis, myocardial infarction, and kidney cancer

164 tis obliterans (n=1), sarcoidosis (n=1), and bronchiectasis (n=1).

165 European Bronchiectasis Network (EMBARC).

166 e infections, the sequelae of infection (eg, bronchiectasis), non-infectious immune-mediated manifest

167 aluation of this patient 10 yr earlier noted bronchiectasis, normal sweat electrolytes, pancreatic su

168 s suggested by the observation that familial bronchiectasis occurs in a rare group of individuals wit

169 ing for atypical CF alleles in patients with bronchiectasis of undetermined cause even in the presenc

170 -three percent of patients (68 of 82) showed bronchiectasis of varying severity.

171 Patients with bronchiectasis often have concurrent comorbidities, but

172 perfusion, vascular attenuation, and central bronchiectasis on chest high-resolution computed tomogra

173 practice who had possible UIP with traction bronchiectasis on HRCT and had not undergone surgical lu

174 Evidence of moderate lower lobe bronchiectasis on HRCT is common in COPD and is associat

175 Twenty-seven of 54 patients (50%) had bronchiectasis on HRCT, most frequently in the lower lob

176 chest to quantify the presence and extent of bronchiectasis or emphysema.

177 onia (OR, 2.3; CI, 1.8-2.9; P < 0.0001), and bronchiectasis (OR, 2.3; CI, 1.1-4.6; P = 0.0193).

178 aving chronic obstructive pulmonary disease, bronchiectasis, or poor lung function increased symptom

179 ry of chronic obstructive pulmonary disease, bronchiectasis, or previous treatment for MAC-PD.

180 r infection scores than did patients without bronchiectasis (P < .005).

181 with mucoid PA correlated significantly with bronchiectasis (P = .041).

182 primarily by chronic pulmonary infection and bronchiectasis, pancreatic exocrine impairment, and elev

183 from cystic fibrosis and non-cystic fibrosis bronchiectasis patients demonstrated an abundance of apo

184 tudy is warranted to further evaluate TSI in bronchiectasis patients.

185 de that the SGRQ reflects impaired health in bronchiectasis patients.

186 nib if they had honeycombing and/or traction bronchiectasis plus reticulation, without atypical featu

187 months of age was associated with persistent bronchiectasis (present on two or more sequential scans)

188 igh-resolution computed tomography-confirmed bronchiectasis provided blood samples for desmosine meas

189 P < 0.0001), and the radiological extent of bronchiectasis (r = 0.29; P < 0.0001).

190 ve cohort study using the TAYBRIDGE (Tayside Bronchiectasis Registry Integrating Datasets, Genomics,

191 cluded chronic obstructive pulmonary disease/bronchiectasis, renal failure, diabetes, depression, and

192 int was change from baseline Quality of Life-Bronchiectasis Respiratory Symptoms scores (QOL-B-RSS) a

193 ncluding 325 with PCD and 88 with idiopathic bronchiectasis, revealed biallelic loss-of-function muta

194 resence at age 3, whereas only the change in bronchiectasis score was related to neutrophil elastase

195 ognostic information when used alongside the Bronchiectasis Severity Index (BSI).

196 scribes the derivation and validation of the Bronchiectasis Severity Index (BSI).

197 e activity in sputum was associated with the bronchiectasis severity index (r = 0.49; P < 0.0001) and

198 nfection with mucoid PA; attempts to prevent bronchiectasis should include reducing exposure to and e

199 morbidity and mortality is mostly caused by bronchiectasis, small airways obstruction, and progressi

200 ith small airway disease and associated with bronchiectasis (Spearman correlation coefficient (r(2) =

201 ticular opacities, volume loss, and traction bronchiectasis superimposed on subacute changes are obse

202 Among patients with non-CF bronchiectasis, the 12-month use of erythromycin compare

203 Among adults with non-CF bronchiectasis, the daily use of azithromycin for 12 mon

204 In bronchiectasis there is a need for improved markers of l

205 intracellulare from patients with underlying bronchiectasis, to establish a nonsequence-based databas

206 ics, and 34 patients with an exacerbation of bronchiectasis treated with intravenous antibiotics.

207 t to determine risk factors for the onset of bronchiectasis, using data collected by the Australian R

208 versus lung disease, and the development of bronchiectasis versus immune-mediated complications, are

209 Bronchiectasis was associated with an increased risk of

210 Bronchiectasis was associated with an independent increa

211 Lower lobe bronchiectasis was associated with lower airway bacteria

212 Bronchiectasis was diagnosed by high-resolution computed

213 At the time of admission bronchiectasis was extensive.

214 rmed a set of interrelated features, whereas bronchiectasis was not associated with any other clinica

215 Bronchiectasis was present in 115 (57.2%) patients.

216 A separate group of 60 patients with stable bronchiectasis was studied on a single visit with the sa

217 ll 118 subjects, median number of lobes with bronchiectasis was three and alveolar consolidation was

218 In a cohort of 182 subjects with bronchiectasis, we found that 9% were colonized with S.

219 In multivariate analyses, risk factors for bronchiectasis were presentation with meconium ileus (od

220 Thirty patients with stable bronchiectasis were recruited and lung clearance index,

221 , 2006, and Nov 22, 2013, 1340 patients with bronchiectasis were screened and 986 patients were analy

222 Patients with non-CF bronchiectasis were stratified by frequency of PA isolat

223 tive lung disease, obstructive lung disease, bronchiectasis) were labelled as major sequelae.

224 es in patients with cystic fibrosis, such as bronchiectasis (which is progressive, irreversible and p

225 PD diagnosis increased except for asthma and bronchiectasis, which decreased between 1990 and 2007, f

226 e is renewed interest in non-cystic fibrosis bronchiectasis, which is a cause of significant morbidit

227 were collected from 17 patients with nodular bronchiectasis who were elderly (mean age 66 yr), predom

228 ently nonsmoking, adult patients with non-CF bronchiectasis with a history of 2 or more infective exa